Stockreport

Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Larimar Therapeutics, Inc.  (LRMR) 
PDF Open label extension (OLE) study is progressing with all 7 sites activated; interim data planned for Q4 2024Selected by Food and Drug Administration (FDA) to participate [Read more]